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Inhibitors of the HIV aspartyl protease [HIV protease inhibitors
(HIV-PIs)] are the cornerstone of treatment for HIV. Beyond their
well-defined antiretroviral activity, these drugs have additional
effects that modulate cell viability and homeostasis. However,
little is known about the virus-independent pathways engaged
by these molecules. Here we show that the HIV-PI Nelfinavir
decreases translation rates and promotes a transcriptional program
characteristic of the integrated stress response (ISR). Mice treated
with Nelfinavir display hallmarks of this stress response in the liver,
including α subunit of translation initiation factor 2 (eIF2α) phos-
phorylation, activating transcription factor-4 (ATF4) induction, and
increased expression of known downstream targets. Mechanisti-
cally, Nelfinavir-mediated ISR bypassed direct activation of the eIF2α
stress kinases and instead relied on the inhibition of the constitutive
eIF2α dephosphorylation and down-regulation of the phophatase
cofactor CReP (Constitutive Repressor of eIF2α Phosphorylation; also
known as PPP1R15B). These findings demonstrate that the modula-
tion of eIF2α-specific phosphatase cofactor activity can be a rheostat
of cellular homeostasis that initiates a functional ISR and suggest
that the HIV-PIs could be repositioned as therapeutics in human
diseases to modulate translation rates and stress responses.
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In mammalian cells, metabolic and environmental stresses, suchas viral infection, nutrient deprivation, and perturbation of
endoplasmic reticulum (ER) homeostasis, converge on the
phosphorylation of the α subunit of translation initiation factor 2
(eIF2α) to trigger an adaptation program known as the in-
tegrated stress response (ISR) (1). Phosphorylation of eIF2α
occurs on serine 51 and negatively regulates the guanine nucle-
otide exchange factor eIF2B, impairing the recycling of eIF2 to
its active GTP-bound form (2). This signaling event inhibits the
initiation steps in mRNA translation, leading to a decrease of
global translation rates. Concomitantly, the phosphorylation of
eIF2α selectively increases the translation of a subset of genes,
including the activating transcription factor-4 (ATF4) (3). To-
gether, translational and transcriptional reprogramming orches-
trates the stress response and homeostasis restoration.
The initiation of the ISR relies on four evolutionarily related
eIF2α kinases that each senses specific insults and signals by
phosphorylating eIF2α (4). On the other hand, dephosphoryla-
tion of eIF2α and subsequent restoration of the translational
capacity is emerging as a key event that controls the complete
recovery from stress and ISR termination. Two cellular cofactors
of the protein phosphatase-1 (PP1c) can specifically reverse the
phosphorylation of eIF2α. The first one is GADD34, which is
induced by the ISR to specifically direct PP1c to dephosphory-
late eIF2α (5–7), allowing termination of the response and res-
toration of the homeostatic pace of translation (7, 8). The second
one is the protein CReP (Constitutive Repressor of eIF2α
Phosphorylation), also known as PPP1R15B, that is expressed
ubiquitously in unstressed cells and was identified as a key factor
maintaining low levels of eIF2α phosphorylation (9, 10). Mole-
cules that promote the activation of the eIF2α kinases or mod-
ulate the dephosphorylation of eIF2α have been identified and
are being considered as potential therapeutics in human diseases
characterized by loss of cellular homeostasis including cancer,
metabolic deregulation, and neurodegenerative diseases (11–13).
It is becoming more and more evident that even the most
thoughtfully designed drugs elicit promiscuous interaction pro-
files within cells (14), and accordingly, many biological effects of
these drugs lack a compelling molecular explanation (14, 15).
This is particularly true for molecules such as Nelfinavir that may
interact with multiple off-targets (16). Beyond understanding the
off-target effects of the drugs, the study of these molecular
mechanisms provides an opportunity to identify cellular path-
ways of biological relevance. Nelfinavir is an HIV protease in-
hibitor (HIV-PI) that was developed in the 1990s, and its in-
corporation into highly active antiretroviral therapy (HAART)
led to remarkable suppression of HIV replication in patients.
The HIV-PIs were among the first drugs to reach the clinic that
were developed with computer technology applied to compound
design based on the X-ray structures. Although these drugs were
designed to specifically inhibit the HIV aspartyl protease, they
display a wide range of activities independently of their ability to
target HIV (17, 18). Clinical trials are underway to evaluate
the effectiveness of HIV-PIs on suppressing tumor progression
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(17, 19). It was proposed that ER stress contributes to their
antineoplastic activity (20–22). However, a detailed character-
ization of the stress responses triggered by the HIV-PIs has not
been reported.
Here we investigated the mechanisms leading to activation of
cellular stress responses in the presence of the HIV-PIs. We
found that these inhibitors, such as Nelfinavir, only triggered a
partial ER-stress response characterized by the absence of
detectable PKR-like endoplasmic reticulum kinase (PERK)
or ATF6 activation or accumulation of misfolded proteins
within the ER. However, Nelfinavir affected proteostasis by
eliciting a robust ISR. It did so by modulating constitutive de-
phosphorylation of eIF2α, therefore bypassing direct activation
of the eIF2α kinases. These findings highlight the relevance of
the modulation of eIF2α-specific phosphatase cofactor activity as
a mechanism that can sense and respond to perturbations of
cellular homeostasis.
Results
The HIV-PIs Trigger a Limited Unfolded Protein Response. To identify
stress pathways engaged by the HIV-PIs, we carried out RNA
sequencing (RNA-seq) on HeLa cells treated for 6 h with Nelfinavir
or its carrier DMSO (Dataset S1). We used a drug concentration
in accordance with the levels found in Nelfinavir-treated patients,
which can reach 10 μM in the plasma and can be 4–5-fold higher
in peripheral blood mononuclear cells (23, 24). A heat map of
mRNA expression revealed a group of genes that were signifi-
cantly induced upon treatment with Nelfinavir (Fig. 1A). We then
investigated the functional impact of Nelfinavir, using AmiGO
software to search for Gene Ontology term enrichment (25).
Response to ER stress was the most significant functional category
enriched among Nelfinavir up-regulated genes (Fig. 1B and Dataset
S2). This observation is consistent with previous studies reporting
the activation of ER-stress–related genes such as GADD34 and
CHOP in cells treated with Nelfinavir (20, 21, 26, 27). To get more
insight on the type of response engaged by Nelfinavir, we compared
this signature with a dataset dissecting the ER-stress response in
mouse embryonic fibroblasts (MEFs) (28). We found that among
the 32 genes up-regulated in both studies, 30 were previously
identified in the ER-stress study as targets of the transcription
factor ATF4 (28) (Fig. 1C and Dataset S3). Moreover, of the two
exceptions, STC2 has also been reported to be an ATF4-induced
gene in another study (29). To confirm these results, we interro-
gated the expression of a panel of ER-stress–induced genes upon
treatment with Nelfinavir. The expression of ATF4-dependent
genes such as GADD34, TRIB3, and SESN2 was increased to
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Fig. 1. Nelfinavir triggers an ATF4 transcriptional response. (A–C) Triplicates of HeLa cells treated 6 h with DMSO or 20 μM NFR were analyzed for gene
expression by RNA-seq. (A) Heat map showing the 153 Nelfinavir up-regulated genes with a P value < 0.01. The genes are listed in order of statistical sig-
nificance. The z score is based on the mean of the six samples; green color indicates high expression and red low expression. The Right panel shows the 20
most significantly induced genes. Each column represents the data of one experiment; purple and pink dots refer to ATF4 only and ATF4 and CHOP targets,
respectively, as reported in C. (B) Gene ontology analysis for the genes identified in A. (C) Venn diagram showing the overlap between the NFR-induced genes
(with a P value < 0.05) in HeLa cells (yellow) and the published tunicamycin (TM)-triggered ER-stress signature (orange) identified in MEFs (28). Note that 30 of
the 32 overlapping genes were reported to be ATF4 only (purple) or ATF4 and CHOP (pink) target genes (28). (D) ATF4 WT and ATF4 −/− MEFs treated for 6 h
with the indicated concentration of NFR or TM were analyzed for expression of indicated genes by real-time PCR relative to β-actin (data are presented as fold
change compared with untreated cells, and mean and SEM of technical triplicates of one representative experiment are shown).
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levels comparable to the expression observed in the presence of
Tunicamycin, a glycosylation inhibitor that triggers a classical ER-
stress response (Fig. 1D). In contrast, when we extended this
analysis to additional ER-stress genes previously shown to be
ATF4-independent, such as EDEM, ERdj4, or HERP, we found
that Nelfinavir, compared with Tunicamycin, induced no or only
weak expression of these transcripts (Fig. 2A). Moreover, in the
presence of Nelfinavir, we could not detect activation of the ER-
stress sensor ATF6, as monitored by liberation of its cleaved
fragment (Fig. 2B). We did not observe an effect of Nelfinavir on
Tunicamycin-mediated ATF6 cleavage; thus, Nelfinavir does not
inhibit the ATF6-specific proteases S1P and S2P (Fig. 2B, lanes
5 and 6). Similarly, Nelfinavir did not promote the accumu-
lation of high-molecular weight complexes containing the ER
chaperone BiP (Fig. 2C), which is usually associated with the
presence of misfolded proteins (13, 30). These findings suggest
that Nelfinavir initiates an ATF4-dependent transcriptional program
rather than a typical ER-stress response.
We assessed the protein expression of ATF4 and its down-
stream target CHOP in MEFs treated for 6 h with increasing
doses of Nelfinavir. ATF4 expression was efficiently induced at
Nelfinavir concentrations above 5 μM (Fig. 3A). In a time course
experiment using 20 μM Nelfinavir, induction of ATF4 occurred
as early as 1 h after treatment, indicating that the activation of
this stress pathway is a rapid event (Fig. 3B). This response is
sustained over time, as shown in HeLa cells treated for 14 h with
increasing concentration of Nelfinavir (Fig. S1 A and B). Gene
induction and ATF4 production was robust and observed above
concentration around 2–5 μM. Investigation of a panel of HIV-
PIs used in the clinic as well as hydroxy-t-butylamidenelfinavir
(M8), the active Nelfinavir metabolite, showed that most HIV-
PIs trigger robust ATF4 expression (Fig. 3C). Nevertheless, we
consistently found that among the HIV-PIs, Nelfinavir initiates
the most robust ATF4 activation in all tested mouse and human
cell types. Altogether these data indicate that Nelfinavir triggers
a transcriptional response mostly characterized by the selective
activation of ATF4.
Nelfinavir Induces a Robust ISR. Expression of ATF4 is usually
dependent on the phosphorylation of eIF2α at serine 51, the
effector branch of the ISR (31). Compared with the response
observed in the presence of ER-stress inducer Tunicamycin,
we found that treatment with Nelfinavir triggered a strong
and sustained eIF2α phosphorylation and concomitant ATF4
expression (Fig. 3D). Accordingly, Nelfinavir-mediated ATF4
and CHOP induction was impaired in MEFs homozygous for the
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Fig. 2. Nelfinavir does not trigger a classical UPR. (A) WT MEFs were treated
for 6 h with indicated doses of NFR (dark gray bars) or Tunicamycin (TM) (light
gray bars). Induction of XBP-1/ATF6–dependent genes Calreticulin, BiP, EDEM,
p58IPK, HRD1, Grp94, ERdJ4, and HERPwas measured by real-time PCR relative
to β-actin (mean and SEM of technical triplicates of one representative ex-
periment are shown). (B) Immunoblot of ATF6 inWTMEFs treated for 6 h with
the indicated concentration of NFR, TM (10 μg/mL), or a combination of NFR
and TM. Arrows represent full-length (ATF6) and cleaved ATF6 (cATF6) as in-
dicated. Asterisk shows unglycosilated ATF6. Tubulin (Tbl) is used as loading
control. (C) Immunoblot of BiP in aggregated insoluble fraction and in total
extracts of HeLa cells treated with TM (2 μg/mL) or indicated doses of NFR for
16 h. Tubulin (Tbl) is used as the loading control.
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Fig. 3. Nelfinavir promotes the production of the ATF4 transcription factor.
(A and B) WB analysis of ATF4 and CHOP expression in WT MEFs treated for
6 h with increasing doses of NFR (A) or with 20 μM NFR for the indicated
times (B). (C) HeLa cell response to increasing doses of different HIV-PIs and
NFR metabolite M8. Cells were treated for 6 h and analyzed by WB for ATF4
expression. (D) WB analysis (Upper panel) and quantification (Lower panels)
of a time course of NFR (20 μM) or TM (10 μg/mL) treatment in HeLa cells.
Immunoblot for p-eIF2α shows a robust and sustained eIF2α phosphorylation
over time with NFR that correlates with ATF4 expression. Tubulin (Tbl) is
used as the loading control.
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phosphorylation-deficient mutant of eIF2α, eIF2α(S51A) (Fig. 4A).
To evaluate the contribution of eIF2α phosphorylation to the
Nelfinavir-mediated transcriptional program, we carried out RNA-
seq on eIF2α(WT) or eIF2α(S51A) MEFs treated with DMSO or
Nelfinavir. We found that 646 genes were up-regulated at least
twofold by Nelfinavir in MEFs (Fig. 4B and Dataset S4). Most of
these genes (84%) were found to require eIF2α phosphorylation
for optimal induction by Nelfinavir (Fig. 4C and Dataset S5),
demonstrating that the ISR is the major transcriptional program
initiated upon treatment with Nelfinavir. Similar results were
obtained by real-time PCR analysis of eIF2α(WT) or eIF2α(S51A)
MEFs treated with increasing amounts of Nelfinavir or Tunica-
mycin (Fig. 4D). In tumors, eIF2α phosphorylation is often
detected in the context of chemotherapy- and radiotherapy-
mediated cell death (32). We compared Nelfinavir-mediated
eIF2α phosphorylation and ATF4 activation with other treat-
ments used or considered as anticancer therapeutics. Compared
with the drugs tested, short-term treatment with Nelfinavir elicits a
stronger response similar to Bortezomib, an inhibitor of the
proteasome that can cause ER stress (Fig. S1C). Collectively,
these findings demonstrate that Nelfinavir is a potent activator of
the ISR.
Nelfinavir Promotes the Activation of ATF4 and the ISR in the Liver of
Treated Mice. To test whether Nelfinavir triggers the ISR re-
sponse in vivo, we injected Nelfinavir intraperitoneally as described
previously (33). Mice treated with 100 mg/kg were killed and
Nelfinavir concentrations were measured in the serum and liver
(Fig. 5A). We found that serum concentration was in the range of
1,000 μg/L (1.67 μM) to 3,000 μg/L (5 μM), with a median con-
centration of 1,757 μg/L. A study in treated HIV patients reported
median concentrations of Nelfinavir of 1,632 μg/L for patients
with Nelfinavir administrated 1,250 mg twice daily and 1,862 μg/L
for patients under a 750 mg thrice daily regimen (34). This in-
dicates that our mouse model recapitulates the concentrations
observed in patients. Moreover, Nelfinavir concentrations in the
liver reflected the amount found in HeLa cells treated for 6 h
with 5–10 μM Nelfinavir (Fig. 5A), suggesting that in the liver,
Nelfinavir can reach concentrations that can trigger an ISR in
vitro. We therefore tested ISR activation in treated mice. Com-
pared with vehicle-treated mice, NFR treatment augmented the
ATF4 protein level and eIF2α phosphorylation in the liver (Fig.
5B). Expression of known ISR-dependent genes such as CHOP,
CHAC1, as well as ATF4 was significantly increased in the liver
of mice treated with 100 mg/kg of Nelfinavir (Fig. 5C). Through
expression studies in MEFs, we found that PPARγ, a nuclear
receptor involved in lipid metabolism, previously shown to be
under the control of ATF4 in the liver (35), was induced by
Nelfinavir treatment in an ATF4-dependent manner (Fig. S1D
and Dataset S5). Increased PPARγ was also observed in the liver
of Nelfinavir-treated mice (Fig. 5D). We analyzed a few addi-
tional metabolic regulators that were identified in the RNA-seq
experiments (Datasets S1 and S5) and found increased expres-
sion of genes involved in lipid metabolism such as the Apolipo-
protein B Receptor (ApoBr), Cholesterol 25-Hydroxylase (Ch25h),
and Sterol O-Acyltransferase 2 (Soat2). Together these results
indicate that Nelfinavir-mediated ISR can affect gene expression
and metabolic responses in vivo.
ISR Activation Bypasses Direct Activation of the eIF2α Kinases. In the
context of ER stress, the ISR component of the ER-stress re-
sponse is mediated by the eIF2α-kinase PERK. To interrogate
PERK involvement in mediating Nelfinavir-induced ISR, we
treated PERK-sufficient and -deficient MEFs with Nelfinavir or
Tunicamycin. As expected, Tunicamycin induced expression of
ATF4 and CHOP in a PERK-dependent manner (Fig. 6A,
compare lane 5–6 and 11–12, and Fig. 6B). In contrast, Nelfinavir-
mediated ISR was unaffected by PERK deficiency (Fig. 6 A and
B and Fig. S2A). These data are consistent with the observation
that Nelfinavir triggers only a partial ER-stress–like response
and raised the question of the possible involvement of other
eIF2α kinases. We analyzed MEFs deficient for PKR, GCN2,
and HRI and found that deletion of any of the three eIF2α
kinases does not alter Nelfinavir-mediated ISR responses, as
measured by Western blot detection of ATF4 and CHOP ex-
pression and eIF2α phosphorylation (Fig. 6C) or by quantitative
measurement of CHOP mRNA (Fig. 6D). As expected, the re-
sponse induced by the well-known ISR stimuli poly(I:C) lipo-
fection, lack of amino acids, or arsenite treatment required PKR,
GCN2, and HRI, respectively (Fig. 6C, compare lanes 11 and 12
for each panel). Note that in this experimental setup, poly(I:C)
does not induce a detectable increase in ATF4 expression but
elicits a strong eIF2α phosphorylation that requires PKR (36).
Next, we silenced the expression of the individual eIF2α kinase
in HeLa cells using specific siRNAs. Each siRNA was tested and
selected for its ability to diminish eIF2α kinase protein and
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Fig. 4. NFR-mediated ATF4 transcriptional signature is controlled by eIF2α
phosphorylation. (A) EIF2αWT and eIF2α S51A MEFs treated for 6 h with the
indicated concentration of NFR or TM (10 μg/mL) and analyzed by WB with
the indicated antibodies. In the absence of eIF2α phosphorylation, ATF4 and
CHOP induction are completely abolished. Tubulin (Tbl) is used as the
loading control. (B) Heat map comparing gene up-regulation in eIF2αWT
and eIF2α S51A MEFs treated for 6 h with 20 μM NFR. Genes that were up-
regulated >twofold in eIF2αWT were included and listed in order of fold
induction. Each row corresponds to a single gene. Right panel shows the 30
highly induced genes in eIF2αWT compared with eIF2α S51A MEFs. (C) Pie
chart of the 646 genes induced by NFR >2-fold in eIF2αWT MEFs (identified
in B), of which 544 (84%) showed a reduced or no induction in eIF2α S51A
MEFs. (D) eIF2αWT and eIF2α S51A MEFs treated for 6 h with the indicated
concentration of NFR or TM were analyzed for expression of indicated genes
by real-time PCR relative to β-actin (data are presented as fold change
compared with untreated cells, and mean and SEM of technical triplicates of
one representative experiment are shown).
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mRNA expression (Fig. S3A) and to yield a significant decrease
in eIF2α phosphorylation and subsequent ATF4 expression as
well as in CHOP mRNA induction upon treatment with the
corresponding activating stress signal (Fig. S3 B and C). Con-
sistent with the observations made in knockout cells, silencing of
each eIF2α kinase individually did not affect Nelfinavir responses,
including ATF4 expression, eIF2α phosphorylation (Fig. 6E), and
CHOP transcription (Fig. 6F).
Activation of the eIF2α kinase can be detected by monitoring
its phosphorylation status. To detect active eIF2α kinases, we
used a Phos-tag reagent, which selectively binds to phosphory-
lated amino acid residues (37, 38). Compared with stress signals
that specifically triggered activation of each of the eIF2α kinases,
we did not detect increased phosphorylation of any of the eIF2α
kinases in the presence of Nelfinavir (Fig. 6G). Intriguingly,
these data indicate that Nelfinavir does not promote eIF2α
phosphorylation by directly augmenting the activity of the up-
stream kinases. To test whether Nelfinavir-induced ISR required
the eIF2α kinases at all, we silenced all four eIF2α kinases using
a mixture of specific siRNAs that was, as for the individual
siRNA, tested for its ability to decrease ISR induction by specific
stimuli (Fig. S3, 4K conditions). Reducing the expression of the
four eIF2α kinases together reduced the Nelfinavir-mediated
ISR (Fig. 6 H and I). These results indicate that Nelfinavir-
induced ISR relies on the redundant and basal activity of eIF2α
kinases, without significantly increasing their activity.
eIF2α Dephosphorylation Is Modulated by Nelfinavir. Previous studies
identified CReP as a constitutive repressor of eIF2α phosphoryla-
tion that mediates basal dephosphorylation of eIF2α by recruiting
the phosphatase PP1 (9). We investigated PP1 and CReP expres-
sion levels in Nelfinavir- or Tunicamycin-treated samples. Although
we observed no differences in CReP expression upon Tunicamycin
treatment over time, Nelfinavir triggered a decrease of CReP pro-
tein expression as early as 1 h after treatment (Fig. 7A). Nelfinavir-
induced CReP down-regulation was dose-dependent (Fig. 7B) and
correlated with ATF4 activation.
CReP mRNA has recently been shown to be a target of the
regulated IRE1α-dependent decay (RIDD) process (39). We
therefore tested Nelfinavir-mediated ISR induction in IRE1α-
deficient MEFs. ATF4 and CHOP induction as well as CReP down-
regulation was not affected in IRE1α-deficient cells compared with
control, suggesting that RIDD pathway is not involved in NFR-
mediated CReP decrease (Fig. S2 B–D). Accordingly, the level of
CReP mRNA was not affected by Nelfinavir treatment (Fig. 7C),
indicating that CReP regulation is likely posttranscriptional.
Importantly, Nelfinavir-mediated CReP reduction was main-
tained in MEF eIF2αS51A, showing that it occurs upstream of
eIF2α phosphorylation and did not depend on subsequent in-
hibition of protein translation (Fig. 7D). In line with this result,
we found that Nelfinavir decreased CReP levels in the presence
of cycloheximide, a general inhibitor of protein translation (Fig.
S4A). Moreover, proteasome inhibition with MG132 did not
significantly affect Nelfinavir-mediated CReP protein decrease
(Fig. S4A). Similarly we found that down-regulation of βTRCP1
and βTRCP2, two E3 ligases that bind and regulate CReP pro-
tein levels (40), increased basal CReP levels but did not affect
Nelfinavir-mediated ATF4 induction or CReP decrease (Fig.
S4B). These findings indicate that the Nelfinavir-dependent
regulation of CReP is posttranslational and does not involve the
classical proteasome-dependent degradation pathway.
PP1 is a key cellular phosphatase that catalyzes dephosphory-
lation of many proteins in a highly regulated and specific manner
(41). We tested whether Nelfinavir altered PP1 generic activity.
First, we did not detect PP1 protein changes upon treatment with
Nelfinavir (Fig. 7 A and D). Further, PP1 phosphatase activity (42)
was not affected in cell extracts of Nelfinavir-treated samples (Fig.
S4C). Finally, Nelfinavir did not enhance the phosphorylation of
the PP1 target histone H2AX (Fig. S4D). In contrast, treatment
with the PP1 inhibitor Caliculin A affected PP1 activity and trig-
gered phosphorylation of both eIF2α and H2AX (Fig. S4 D and
E). These data indicate that Nelfinavir does not alter the generic
activity of PP1. To interrogate the possibility that Nelfinavir reg-
ulates the recruitment of the PP1 complex to eIF2α, we generated
a cell line expressing an inducible VSV-tagged eIF2α protein.
Immunoprecipitation of VSV-eIF2α revealed decreased PP1
binding to eIF2α in the presence of Nelfinavir (Fig. 7E). Inter-
estingly, neither Salubrinal nor Guanabenz (two drugs that have
been shown to affect eIF2α phosphorylation by targeting PP1 re-
cruitment to eIF2α) (12, 13) affected CReP protein levels (Fig. 7F).
Thus, the previously described experiments all point to inhibition
of eIF2α dephosphorylation that correlates with decreased CReP
protein levels, as a specific hallmark of the Nelfinavir-mediated
stress response.
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Fig. 5. NFR induces expression of ATF4 target genes in mouse liver. (A) NFR concentration measured in serum and liver of mice injected i.p. for 3 consecutive
days with 100 mg/kg or vehicle (n = 8) and intracellular concentration observed in HeLa cells treated for 6 h with the indicated amount of NFR or vehicle (n =
3). (B) Immunoblot for ATF4, p-eIF2α and total eIF2α level in liver protein extracts of mice injected i.p. for 3 consecutive days with the indicated doses of NFR
(three mice per condition). (C and D) Real-time PCR analysis of the indicated mRNA isolated from the liver of mice injected i.p. for 3 consecutive days with NFR
(100 mg/kg; n = 10) or with the vehicle only (n = 10). P values were determined by a one-tailed unpaired Student’s t test (**P < 0.01, *P < 0.05).
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CReP Is Required for Nelfinavir-Mediated ISR. In accordance with
previous results that showed ISR activation in cells expressing an
shRNA construct targeting CReP (9) or isolated from CReP-
deficient mice (10), we observed increased ATF4 and CHOP
expression in unstressed cells transfected with CReP-specific
siRNAs, as well as in CReP-deficient MEFs (Fig. 8 A–D). The
transcriptional program triggered by CReP deficiency recapitu-
lates the ISR elicited by Nelfinavir; factors such as PPARγ,
CHAC1, and SESN2 were induced, whereas BiP and ERdj4 were
not (Fig. 8C). Moreover, the ISR mediated by CreP deficiency
was reduced when expression of the four eIF2α kinases was si-
lenced (Fig. S5). These data further demonstrate that basal
phosphorylation of eIF2α is a default program in unstressed cells
that is constitutively inhibited by CReP–PP1 complexes to
maintain homeostasis. Interestingly, when we monitored Nelfinavir
responses in CReP-silenced or -deficient cells, we found that
Nelfinavir still partially increased ATF4 expression (Fig. 8 B and
D), suggesting that beyond CReP, Nelfinavir may affect an al-
ternative ISR regulatory pathway. Because GADD34 was in-
creased by CReP deficiency (Fig. 8C), we analyzed ISR activation
in GADD34-deficient MEFs transfected with CReP siRNA (Fig.
8E) as well as in HeLa cells transfected with a combination of
GADD34 and CReP siRNAs (Fig. S6). Nelfinavir no longer
increased ATF4 expression in cells deficient for both CReP
and GADD34, whereas Tunicamycin treatment, which drives
ISR through PERK activation, still induced ATF4 under the
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Fig. 6. NFR triggers eIF2α phosphorylation and downstream effectors independently of the eIF2α kinases PERK, PKR, HRI, and GCN2. (A) PERK+/+ and PERK−/−
MEFs treated for 6 h with the indicated concentration of NFR or TM and analyzed by WB with indicated antibodies. (B) CHOP mRNA level in PERK+/+ and
PERK−/− MEFs treated for 6 h with the indicated concentration of NFR or TM was measured by real-time PCR. (C) PKR−/−, GCN2−/−, and HRI−/− MEFs and their
respective WT control were treated for 6 h with the indicated concentration of NFR or TM (10 μg/mL) and analyzed by WB with the indicated antibodies. Each
cell type was also treated with kinase-specific stimuli; PKR cells were lipofected with p(I:C) (10 μg/mL) for 6 h, GCN2 cells were cultured 6 h in a medium
depleted of amino acid, and HRI cells were treated for 1 h with 50 μM arsenite. (D) CHOPmRNA level in PKR−/−, GCN2−/−, and HRI−/−MEFs and their respective
WT control treated for 6 h with the indicated concentration of NFR or TM (10 μg/mL) was measured by real-time PCR. (E) HeLa cells were transfected with PKR,
HRI, GCN2, PERK, or nonrelevant (NR) siRNA for 48 h and treated for 6 h with NFR (20 μM) or TM (10 μg/mL). Immunoblots were performed with ATF4, p-eIF2α,
and total eIF2α antibodies. (F) CHOP mRNA level was measured by real-time PCR in HeLa cells transfected for 48 h with indicated siRNA and left untreated
(Mock; black bars) or treated for 6 h with 20 μM NFR (gray bars). (G) PERK, PKR, GCN2, and HRI activation was measured using phos-tag SDS/PAGE and specific
antibodies in HeLa cells subjected to the indicated treatments: 6 h NFR or TM to activate PERK; No AA, 6 h medium without amino acids to activate GCN2;
50 μM arsenite for 1 h to activate HRI; p(I:C) (10 μg/mL) was lipofected for 6 h to activate PKR. Tubulin (Tbl) is used as loading control. (H) HeLa cells were
transfected with a mixture of PKR, HRI, GCN2, and PERK siRNA (4K) or nonrelevant (NR) siRNA. At 48 h after transfection, cells were treated for 6 h with NFR
or left untreated (Mock). Immunoblots were performed for the indicated antibodies. (I) CHOP mRNA level was measured by real-time PCR in HeLa cells
transfected for 48 h with the indicated siRNA and left untreated (Mock; black bars) or treated for 6 h with 20 μM NFR (gray bars). Real-time PCRs are rep-
resented as mean and SEM of technical triplicates of one representative experiment.
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same conditions (Fig. 8E). This result suggests that Nelfinavir
affects the GADD34-mediated negative feedback loop and is
consistent with the sustained and robust ISR activation ob-
served with Nelfinavir.
Because inhibition of translation initiation is a key feature of
the ISR and is controlled by the eIF2α phosphorylation status,
we quantified the role of CReP in NFR- or Tunicamycin-mediated
ISR activation by monitoring protein synthesis. As expected, the
mutation in the eIF2α phosphorylation site rescued translation
inhibition in the presence of Tunicamycin or Nelfinavir (Fig. 8F).
However, CReP deficiency only affected Nelfinavir-mediated
translation inhibition without affecting Tunicamycin-mediated
decrease in translation rates (Fig. 8F). These findings further
demonstrate the specific role of CReP in initiating Nelfinavir-
induced ISR and identify CReP modulation as a specific mech-
anism of ISR activation.
Discussion
EIF2α phosphorylation and the ISR are mostly initiated by stress
insults that prime specific eIF2α kinases. EIF2α dephosphory-
lation events, on the other hand, are considered as negative
feedback loops that regulate the intensity and duration of the
response. Here we identify modulation of eIF2α dephosphory-
lation and CReP down-regulation as the initiating event driving
Nelfinavir-dependent transcriptional reprogramming. Both
Nelfinavir and CReP deficiency trigger a comparable response that
is only impaired in the absence of the four eIF2α kinases. These
results exclude the hypothesis that Nelfinavir activates a unique
eIF2α kinase. Instead, they suggest that the four known eIF2α
kinases (i.e., PERK, GCN2, HRI, and PKR) have basal and
redundant activity by default and that CReP is a key guardian of
cellular integrity that keeps the ISR switched off. The finding
that the CReP level can be pharmacologically modulated raises
the possibility that other cellular mechanisms may regulate
CReP activity to trigger this specific cellular stress response.
Here we show that Nelfinavir is associated with decreased CReP
protein levels, however whether this is the direct cause of ISR
activation is unclear. Indeed, our result showing that PP1 asso-
ciation with eIF2α decreases upon NFR treatment (Fig. 7E)
suggests that NFR-mediated CReP decline could be an indirect
consequence of a functional regulation of the eIF2α phosphatase
complex. In line with this idea, we showed that upon NFR
treatment, GADD34, the inducible eIF2α-specific cofactor of
PP1, is expressed but cannot compensate for the loss of CReP,
suggesting that NFR interferes with GADD34 function. Ac-
cordingly, GADD34 silencing impaired the remaining NFR-
mediated ISR activity observed in CReP-deficient cells. It is
likely that identification of Nelfinavir’s cellular targets will help
define the mechanisms controlling CReP levels and phosphatase
complex activity. If this mechanism is probably complex and may
rely on binding to multiple targets (16), the common biological
properties shared by the HIV-PIs may also reflect their common
specific chemical properties. Most HIV-PIs are peptidomimetics
that were designed based on a synthetic analog of the peptide
bond between phenylalanine and proline at positions 167 and
168 of the gag–pol polyprotein, a target of the HIV protease
(43). Therefore, we cannot exclude that these common struc-
tures shared by HIV-PIs could engage a specific proteostasis
sensor to initiate the ISR.
Increased eIF2α phosphorylation is associated with several
pathophysiological conditions including neurodegeneration, cancer,
diabetes, and obesity (44–46). Long-term treatment with the
HIV-PIs is associated with adverse effects such as hyperlipidemia
or hypolipidemia, body fat redistribution, osteopenia and oste-
oporosis (47), as well as insulin resistance and susceptibility to
type II diabetes (48–51). Interestingly, loss-of-function mutation
in CReP protein leading to decreased PP1 binding and sustained
eIF2α phosphorylation has recently been shown to drive β-cell
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Fig. 7. Nelfinavir modulates constitutive eIF2α dephosphorylation. (A) Time course of NFR (20 μM) or TM (10 μg/mL) treatment in HeLa cells. Immunoblot for
indicated antibodies shows CReP down-regulation in NFR-treated cells, which correlates with ATF4 induction. PP1 level is not affected. Lower panel showed a
WB quantification for CReP and ATF4 protein level over time in NFR- and TM-treated HeLa cells. (B) HeLa cells were treated for 6 h with increasing doses of
NFR and analyzed by WB using the indicated antibodies. NFR induced CReP down-regulation in a dose-dependent manner. (C) CRePmRNA level in HeLa cells
treated for 6 h with the indicated concentration of NFR (dark gray bars) or with TM (10 μg/mL; light gray bars) was measured by real-time PCR relative to
β-actin (mean and SEM of technical triplicates of one representative experiment). (D) EIF2αWT and eIF2αS51A MEFs treated for 6 h with the indicated
concentration of NFR or with TM (10 μg/mL) and analyzed by WB with the indicated antibodies. Untreated CReP+/+ and CReP−/− MEFs were used as positive
control for antibody specificity. Asterisk shows an unspecific band, and PP1 is used as loading control. (E) HEK293T cells stably expressing a doxycycline (DOX)-
inducible version of VSV-eIF2α were treated as indicated (DOX 1 μg/mL for 24 h followed by NFR 20 or 40 μM for 6 h). VSV-eIF2α, PP1, and CReP protein levels
were analyzed by WB using specific antibodies after anti-VSV immunoprecipitation (IP; Upper panel) and in total cell lysates (Input; Lower panel). Association
of PP1 and CReP with VSV-eIF2α is impaired in NFR-treated samples. (F) HeLa cells were treated for 24 h with the indicated concentration of NFR, Salubrinal
(Sal), or Guanabenz (Gua) and analyzed by WB for CReP, ATF4, p-eIF2α, and total eIF2α expression level. Tubulin (Tbl) is used as the loading control.
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dysfunction and metabolic defects that can lead to diabetes in
human (52). Elevated levels of ISR markers (such as ATF4 or
eIF2α phosophorylation) in the liver of NFR-treated mice sug-
gest that activation of this pathway may contribute to the side
effects observed in HIV-PI–treated patients. Indeed, ATF4 is
known to play a key role in osteoblast differentiation (53) and its
transgenic expression in osteoclasts promotes severe osteopenia
(54). Therefore, bone diseases found in HIV-PI–treated patients
could be linked to the deregulation of this transcription factor. In
addition, these patients present defects in metabolic pathways
including lipid metabolism where ATF4 was shown to play an
important role (55, 56). Studies in ATF4-deficient mice have
shown that the ATF4 transcriptional program may affect lipolysis
and expression of lipogenic genes (57). Moreover, it was pre-
viously reported that mice with enforced expression of an active
C-terminal fragment of GADD34 to attenuate eIF2α phos-
phorylation have decreased expression of key hepatic transcrip-
tional regulators of intermediary metabolism including PPARγ
(58). In line with these findings, we observed that PPARγ is up-
regulated in liver of mice upon NFR treatment. PPARγ, is a
master regulator of key proteins involved in lipid metabolism,
vascular inflammation, and proliferation that can affect multiple
cell types, including hepatocytes, macrophages, endothelial cells,
and vascular smooth muscle cells. Its possible contribution to
side effects in HIV patients treated with HIV-PIs is therefore
likely multifaceted and may involve different pathways possibly
beyond lipid metabolism. We identified other genes related to
lipid metabolism whose expression is up-regulated in the liver of
NFR-treated mice, including Soat2 (also abbreviated as Acat2),
which was also found among the top genes up-regulated in MEFs
in an eIF2α phosphorylation-dependent manner. This enzyme
contributes to cholesterol ester synthesis in the small intestine
and liver and therefore can promote hypercholesterolaemia and
atherosclerosis (59), two metabolic disturbances often observed
in HIV-PI–treated patients. All together these data further show
that the ISR is a key metabolic regulator that can affect multiple
pathways related to lipid metabolism. It is therefore likely that
sustained ISR activation may account for some of the metabolic
deregulations associated with the use of HIV-PIs in patients. In
this context, ISRIB, a small molecule that potently inhibits the
effects of eIF2α phosphorylation (60–62), could become an in-
teresting therapeutic option to alleviate ISR-associated meta-
bolic alterations in HIV-PI–treated patients.
Another important question is whether the HIV-PI–induced
ISR could contribute to their antitumoral activity. Numerous
clinical trials are underway to address the efficacy of these drugs
in a variety of human tumors, but so far the underlying mecha-
nisms are unknown (19). Whereas induction of ISR by blocking
dephosphorylation of eIF2α is an adaptation program that in-
creases the survival of stressed cells (9), strategies aimed at in-
creasing eIF2α phosphorylation were found to limit cancer cell
proliferation and tumor growth (12, 63). Similarly, in a genome-
wide functional screen, CReP down-regulation was identified to
increase sensitivity to tamoxifen (64). The outcome of fine-tun-
ing the eIF2α phosphorylation level under intratumoral stresses
is likely to affect the balance between death and survival (44, 65,
66). It is therefore tempting to speculate that sustained phar-
macological activation of ISR could modify the cell fate decision
process and tilt the balance in favor of death. Thus, a possible
contribution for the ISR in mediating Nelfinavir anticancer
properties is a plausible hypothesis that needs to be tested.
In addition to promoting ATF4 expression, the ISR decreases
translation rates—a feature that could be relevant in human
diseases characterized by perturbation of cellular proteostasis,
such as protein misfolding and aggregation diseases. Slowing
down translation rates can significantly improve protein folding,
therefore contributing to reestablishment of homeostasis in these
diseases (67–69). Drugs such as Salubrinal (11) and Guanabenz
(13) or Sephin 1 (70), which were described as selective inhibi-
tors of cellular complexes that dephosphorylate eIF2α, have
been considered toward that purpose and showed promising
results in animals. Nelfinavir has the advantage of being a rather
safe compound with well-known pharmacology; it has been
tested and used in thousands of cancer and HIV patients over
many years. Our data show that repositioning this compound to
promote the ISR and down-regulate translation rates in patients
with misfolding and aggregation diseases should be considered
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Fig. 8. CReP regulation is sufficient to trigger ISR. (A) ATF4, CHOP, and CReP
mRNA level in HeLa cells transfected for 24 h with nonrelevant (NR) siRNA or
two different CReP-specific siRNAs were measured by real-time PCR relative
to β-actin (mean and SEM of technical triplicates of one representative ex-
periment). (B) HeLa cells were transfected for 24 h with the indicated siRNA
and treated or not with 20 μM NFR. Immunoblot shows that CReP silencing is
sufficient to induce a robust eIF2α phosphorylation, leading to ATF4 and
CHOP induction. (C) CReP−/−MEFs (gray bars) and WT control (CReP+/+; black
bars) were compared for the mRNA level of indicated genes by real-time PCR
relative to β-actin (mean and SEM of technical triplicates of one represen-
tative experiment). (D) CReP−/− MEFs and WT control (CReP+/+) were treated
for 6 h with NFR at the indicated concentration and TM (10 μg/mL) and
analyzed by WB for ATF4 expression and eIF2α phosphorylation. (E) GADD34
ΔC/ΔC MEF and WT control cells were transfected for 24 h with nonrelevant
(NR) or CReP-specific siRNA and treated for 6 h with NFR or TM (10 μg/mL).
WB analysis using indicated antibodies shows that both CReP and GADD34
silencing are required to abolish NFR-mediated eIF2α phosphorylation and
ATF4 induction, whereas in the same condition TM is still able to increase the
ATF4 level. (F) Quantification of newly synthesized proteins at 0, 2, 4, and 6 h
after 10 μg/mL TM (Left panels) or 20 μM NFR (Right panels) treatment in
indicated MEFs (eIF2αWT, eIF2α S51A, CReP+/+, and CReP−/−). Treated cells
were labeled for 15 min with [35S]methionine and visualized by SDS/PAGE
and subsequent autoradiography. Autoradiography was quantified, and
results show percentage of translation compared with untreated cells. The
mean and SEM of three independent metabolic labeling experiments are
shown. P values were determined by a one-tailed unpaired Student’s t test
(***P < 0.001, **P < 0.01, *P < 0.05).
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and may represent a new approach to restore folding and ho-
meostasis in these pathologies.
Materials and Methods
High-throughput sequencing, statistical analysis, lentivirus production, cell
line infection, BiP aggregation assay, metabolic labeling, siRNA transfection,
immunoprecipitation, and phosphatase activity assay are described in SI
Materials and Methods.
Cell Culture and Drug Treatment. All cell lines were cultured in DMEM
supplemented with 10% (vol/vol) FBS, antibiotics (1% PSN; penicillin
5 mg/mL, streptomycin 5mg/mL, and neomycin 10mg/mL from Gibco-Life
Technologies), 1% nonessential amino acids (Gibco-Life Technologies) and
1% L‐glutamine (AMIMED, Bioconcept). Cells were not tested for myco-
plasma contamination during the study. Each knockout or transgenic MEF
cell line was compared with littermate control. Table S1 shows the origin
and provider of every MEF cell lines used in these study.
Nelfinavir Mesylate (CAS 159989–65-8) was from Axon Medchem; Rito-
navir, Atazanavir, Lopinavir, and Saquinavir were obtained from The NIH
AIDS Reagent Program; and Nelfinavir hydroxy-tert-butylamide (M8) and
Oxaliplatin were from Santa-Cruz. Tunicamycin, sodium arsenite solution,
Rapamycin, and Cycloheximide were from Enzo-Life Sciences. Guanabenz,
Salubrinal, Doxycycline, (Z)-4-Hydroxytamoxifen, Etoposide, and MG132
were from Sigma-Aldrich. Calyculin A, Bortezomib, and Imatinib were from
LC-Laboratories, and Okadaic acid was from Santa-Cruz. Poly(I:C) HMW (In-
vivogen) was lipofected using Lipofectamin2000 (Life Technology).
Mice. Animal experiments were approved by the Veterinary Office of the
Canton de Vaud and the Animal Ethics Committee (authorization 2390). WT
C57BL/6J mice were housed at the University of Lausanne in accordance with
local and national guidelines. Female mice 6–8 wk old were randomly dis-
tributed in two groups and injected intraperitoneally for 3 consecutive days
either with vehicle [4% (vol/vol) DMSO, 5% (vol/vol) PEG, 5% (vol/vol) Tween
80 in saline] or with 100 mg/kg NFR as described previously (33, 71). Mice
were killed 6 h after the last injection, and livers were harvested for protein
and mRNA analysis. Experiments were repeated three times with 3–10 mice
per group. One representative experiment with three mice per group is
shown for Western blot (WB) analysis. One representative experiment with
10 mice per group is shown for mRNA level quantification by real-time PCR.
Measurement of NFR Concentration. The quantification of nelfinavir in plasma,
liver tissue, and cells has been performed with the stable isotope labeled internal
standard method using an adaptation of the assay by liquid chromatography
tandem mass spectrometry developed in our laboratory (72).
RNA Extraction and RT-PCR. Total RNA from cells and tissues was extracted
with PeqGOLD TriFast (PeqLAB) according to the manufacturer’s instructions,
and cDNA was synthesized with a High Capacity cDNA Reverse Transcription
kit (Applied Biosystems). SYBR Green fluorescent reagent and LightCycler480
Real Time PCR System from Roche were used for quantitative RT-PCR. The
relative amount of mRNA was calculated by the comparative threshold cycle
method with β-actin as control. Primer sequences are described in Table S2.
siRNA Transfection. Specific and nonrelevant siRNA were purchased from
Qiagen and listed in Table S3. Cells were transfected with Lipofectamine
RNAiMAX Transfection Reagent (Life Technology) according to the manu-
facturer’s instructions.
Immunoblot Analysis. EveryWB shown in the study is representative of at least
three independent experiments performed in the same conditions.
Cells and liver protein extracts were prepared with RIPA (radio-
immunoprecipitation assay) buffer (50 mM NaCl, 50 mM Tris pH 7,4, 1 mM
EDTA, 0.1% SDS, 1% Nonidet P-40, 1% Sodium Deoxycholate) supplemented
with protease inhibitors mixture (Roche) and 5 μM MG132 (Sigma-Aldrich).
Extracts were separated by SDS/PAGE and transferred to nitrocellulose
blotting membranes (Amersham). PERK, PKR, GCN2, and HRI phosphoryla-
tion was monitored by Phos-tag SDS/PAGE (38). The following antibodies
were used for immunoblot analysis: anti-ATF4 (Santa Cruz; sc-200), anti–
phospho-eIF2α (Cell Signaling; #3597S), anti–total-eIF2α (Cell Signaling;
#9722S), anti-IRE1α (Cell Signaling; #3294), anti-PERK (Cell Signaling; #3192),
anti-HRI (Santa Cruz; sc-30143), anti-GCN2 (Cell Signaling; #3302), anti-PKR
(Santa Cruz; sc-6282), anti-CHOP (Cell Signaling; #2895S), anti-Tubulin
(Adipogen; F2C), anti-HsCReP (Proteintech Group; 14634–1-AP), anti-GADD34
(Proteintech Group; 10449–1-AP), anti-mouse CReP (kindly provided by David
Ron, University of Cambridge, Cambridge, UK) (10), anti-VSV (Sigma-Aldrich;
Clone P5D4), anti-PP1 (Santa Cruz; sc-6108), anti–phospho-H2AX (Upstate;
07–164), polyclonal anti-ATF6 (obtained from Laurie H. Glimcher and Ann-
Hwee Lee, Weill Cornell Medical College, New York, NY) (73), and anti-BiP
(Cell Signaling; #3177S).
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